Effects of somatostatin analogs on kidney weight per body weight, cyst area, and renal function.

<p>Male PCK rats were assigned randomly to 4 groups (<i>n</i> = 6 per each): treated with 8 mg/kg octreotide long-acting release alone (OCT), 8 mg/kg pasireotide long-acting release alone (PAS), co-application of both (OCT/PAS), or vehicle (microparticles liquid; CONT) from 4 to 16 weeks of age. Kidney weight per body weight (KB %, A), cyst area (% of total field, B), and serum urea nitrogen (SUN, mg/dL, C) of individual kidneys are shown by scattered plots. Difference between CONT and each drug-treated group, *: <i>P</i> < 0.05, **: <i>P</i> < 0.01. Comparison between OCT and PAS or OCT/PAS, $: <i>P</i> < 0.05, $ $: <i>P</i> < 0.01. There was no statistically significant difference between the PAS and OCT/PAS groups in each measurement.